

Bandeiraea (Griffonia) simplicifolia lectin-I, isolectin A₄, reacting with Tn (GalNAc α 1 \rightarrow Ser/Thr) or galabiose (Gal α 1 \rightarrow 4Gal) containing ligands

Albert M. Wu^{a,*}, June H. Wu^b, Shuh-Chyung Song^a, Elvin A. Kabat^c

^aGlyco-Immunochemistry Research Laboratory, Institute of Molecular and Cellular Biology, Chang-Gung Medical College, Kwei-san, Tao-yuan, Taiwan

^bDepartment of Microbiology and Immunology, Chang-Gung Medical College, Kwei-san, Tao-yuan, Taiwan

^cDepartment of Microbiology, Human Genetics and Development, and Neurology, and Cancer Center/Institute for Cancer Research, Columbia University College of Physicians and Surgeons, New York, NY 10032, USA

Received 3 September 1996; revised version received 8 October 1996

Abstract *Bandeiraea (Griffonia) simplicifolia* lectin-I, isolectin A₄(GS I-A₄) reacting with the Tn(GalNAc α 1 \rightarrow Ser/Thr) sequence or human blood group P^k active disaccharide (E, Gal α 1 \rightarrow 4Gal, galabiose) was studied by quantitative precipitin (QPA) and precipitin-inhibition assays. When human blood group P₁ or Tn active glycoproteins were tested by QPA, GS I-A₄ reacted strongly with both the Tn active glycoproteins purified from asialo porcine, ovine and armadillo submandibular glands and a P₁ active glycoprotein isolated from sheep hydatid fluid. They precipitated over 80% of the lectin nitrogen added. The asialo porcine salivary glycoprotein-GS I-A₄ interaction was inhibited by both Tn containing glycopeptides and Gal α 1 \rightarrow 4Gal indicating that GS I-A₄ not only reacts with human blood group A(GalNAc α 1 \rightarrow 3Gal) and B(Gal α 1 \rightarrow 3Gal) active disaccharides, but also recognizes the Tn sequence and the E(Gal α 1 \rightarrow 4Gal) ligand. From these results, the carbohydrate specificity of GS I-A₄ can be defined as A, Tn \geq B and E.

Key words: *Bandeiraea (Griffonia) simplicifolia* lectin-I A₄; Tn-active glycoprotein; Sheep hydatid cyst glycoprotein; Binding property

1. Introduction

The *Bandeiraea (Griffonia) simplicifolia* lectin-I (GS I) is one of two lectin families extracted from the seeds of *B. (Griffonia) simplicifolia* (GS) [1]. It agglutinates human blood group A and B cells and is specific for GalNAc α 1 \rightarrow and

*Corresponding author. Fax: (886) (3) 328-6456 (Lab.); (886) (3) 328-3031 (Col.).

Abbreviations: Gal, D-galactopyranose; Glc, D-glucopyranose; LFuc or Fuc, L-fucopyranose; GalNAc, 2-acetamido-2-deoxy-D-galactopyranose; GlcNAc, 2-acetamido-2-deoxy-D-glucopyranose; GS I-A₄ (BS I-A₄), *Griffonia (Bandeiraea) simplicifolia* lectin-I A₄; GP, glycoprotein; THGP, Tamm-Horsfall glycoprotein; MSM, one of human blood group A active glycoproteins purified from human ovarian cyst fluid [26]; OSM, ovine submandibular glycoprotein-major; ASG-A, armadillo submandibular glycoprotein, fraction A [17] which is one of the sialic acid containing glycoproteins in armadillo submandibular glands; native ASG-Tn [18], a naturally occurring Tn glycoprotein isolated from the extract of armadillo submandibular glands in 0.01 M PBS, pH 6.8 after removal of ASG-A; PSM, porcine salivary GP-major; BSM, bovine submandibular GP-major; QPA, quantitative precipitin assay; QPIA, quantitative precipitin-inhibition assay. Lectin determinants that are used to classify applied lectins [14,30,31] are expressed in bold: A(GalNAc α 1 \rightarrow 3Gal); B(Gal α 1 \rightarrow 3Gal); Tn(GalNAc α 1 \rightarrow Ser/Thr); E(galabiose, Gal α 1 \rightarrow 4Gal) [30,31], the human blood group P^k(Gal α 1 \rightarrow 4Gal β 1 \rightarrow 4Glc-Cer) active disaccharide or part of P₁ determinant structure (Gal α 1 \rightarrow 4Gal β 1 \rightarrow 4GlcNAc β 1 \rightarrow 3-Gal β 1 \rightarrow 4Glc-Cer) at the terminal non-reducing end

Gal α 1 \rightarrow at different strengths [2]. The GS I family is a glycoprotein of M_r 114 000 consisting of four subunits [2]. This family is composed of five tetrameric isolectins with different binding specificities (A₄, A₃B, A₂B₂, AB₃ and B₄) [3], which result from the combination of two different glycoprotein (A and B) subunits. GS I-A₄ is the member that contains only A subunits. This lectin is most specific for GalNAc, but also reacts with Gal α 1 \rightarrow [4]. However, little is known about the interaction of GS I-A₄ with the Tn(GalNAc α 1 \rightarrow Ser/Thr) sequence and the galabiose (E, Gal α 1 \rightarrow 4Gal) ligand. The Tn determinant is one of the simplest carbohydrate chains in which GalNAc α 1 \rightarrow is linked to the Ser/Thr of the protein core. It has been proposed as a marker for cancerous tissues [5–9]. At the surface of the red cell membrane, the Tn transformation indicates an acquired disorder characterized by the exposure of normally cryptic GalNAc residues α \rightarrow linked to the hydroxyl group of Ser or Thr of membrane sialoglycoproteins [10,11]. The Tn antigen can also be detected at the cell surface of erythrocytes, granulocytes, platelets, and B and T lymphocytes of patients presenting the Tn syndrome [12]. Galabiose is the isomer of blood group B active disaccharide (Gal α 1 \rightarrow 3Gal), the structural difference being only in the linkage of carbon-3 and carbon-4, respectively, of the second galactose residue. The Gal α 1 \rightarrow 4Gal sequence is frequently found in the carbohydrate chains of many glycosphingolipids located at the surface of mammalian cell membranes, such as intestinal and red blood cells and is a receptor for the uropathogenic *E. coli* ligand and for toxin attachment [13,14]. Recently, we found that this sequence also functions as an important receptor for toxic lectins, such as abrin-a and mistletoe toxic lectin-I [14,15]. Therefore, it should be useful to define the affinity of GS I-A₄ for these two ligands, Tn and E.

In this study, the binding properties of GS I-A₄ with the Tn determinant and the galabiose ligand were characterized by quantitative precipitin and precipitin inhibition assays. The results showed that GS I-A₄ bound strongly with Tn(GalNAc α 1 \rightarrow Ser/Thr) containing glycoproteins and E(Gal α 1 \rightarrow 4Gal) sequences at their terminal non-reducing ends and these reactions were strongly inhibited by Tn glycopeptides and Gal α 1 \rightarrow 4Gal, indicating that GS I-A₄ is not only reacting with blood group A and B disaccharides but also recognizes the Tn determinant and the E sequence.

2. Materials and methods

2.1. Lectin

The *B. simplicifolia* lectin-I isolectin A₄(GS I-A₄) was purchased from Sigma Chemical Co. (L-3019), St Louis, MO, USA.




Fig. 1. Quantitative precipitin curves of GS I-A₄ with glycoproteins. Conditions: 5.0 µg GS I-A₄ nitrogen; total volume 300 µl.

2.2. Sialoglycoproteins

The major fraction of ovine (OSM), bovine (BSM), and porcine (PSM) submandibular glycoproteins, as well as fraction A of armadillo (ASG-A) submandibular glycoprotein and native ASG-Tn were prepared according to the method of Tettamanti and Pigman [16] or its modification [17-20]. Their chemical composition was analyzed as described previously [16,17].

Human blood group P₁-active glycoprotein [21,22] and Tamm-Horsfall glycoprotein Sd(a+) [23,24] were kindly provided by Dr. W.M. Watkins, University of London, Royal Postgraduate Medical School Hammersmith Hospital, London, UK. The P₁-active glycoprotein

was isolated from sheep hydatid cyst by extraction with 95% w/v phenol. The fraction was phenol insoluble and precipitated between 37 and 40% ethanol [21,22]. The human blood group A glycoprotein (MSM) was purified from human ovarian cyst fluid [25,26]. The crude salivary gland mucus glycoprotein (native BN GP) of the Chinese swiftlet (genus *Collocalia*) was extracted with 66°C distilled H₂O for 20 min from commercial bird nest (BN) [27]. Fetuin and human α₁-acid glycoprotein were purchased from Sigma Chemical Co., St. Louis, MO. USA.

For desialylation, a sample of the native glycoprotein, dissolved in 0.01 M HCl at 4 mg/ml was hydrolyzed at 80°C for 90 min and

Table 1
Comparison of precipitating activities of GS I-A₄ with various glycoproteins^a

Curve in Fig. 1	Glycoprotein (GP)	Maximum precipitated (μg N)	Glycoprotein giving 50% ppt (μg)
a	Asialo porcine salivary GP-major (PSM) (A, A _h , T, Tn) ^b	4.4 (88%) ^c	1.0
	Armadillo submandibular GP (ASG-A) (Tn only)	4.3 (86%)	1.0
	Asialo ASG-A (Tn only)	4.0 (80%)	1.0
	Native ASG-Tn (Tn)	4.2 (84%)	1.0
	Fetuin	0	–
	Asialo fetuin (II, T)	0	–
b	Ovine salivary GP-major (OSM)	1.9 (38%)	–
	Asialo OSM (Tn)	4.4 (88%)	1.0
	Tamm-Horsfall glycoprotein (THGP)	0	–
	Asialo THGP	0	–
c	Sheep hydatid P ₁ active GP (E)	4.6 (92%)	5.0
	Native bird nest P ₁ active GP (cryptic E)	0.1 (2%)	–
	Asialo bird nest P ₁ active GP (E, F)	3.6 (72%)	23.0
d	Cyst MSM 10% ppt (A)	4.3 (86%)	2.0
	Bovine salivary GP-major (BSM)	1.8 (36%)	–
	Asialo BSM	3.9 (78%)	1.5
	Human α ₁ -acid GP	0	–
	Asialo human α ₁ -acid GP (II)	0	–

^aAbbreviations: GP, glycoproteins.

^bThe symbol in parentheses indicates the human blood group activity and/or lectin determinants (A_h, A, E, F, II, Tn, T).

^cThe value in parentheses indicates the % of μg N precipitated at maximum when the amount of lectin added is expressed as 100% (= 5.0 μg N).

dialyzed for 48 h against frequently changed water. The non-dialyzable material was centrifuged to remove insoluble particles and freeze-dried [16,17].

2.3. Sugar inhibitors

Tn glycopeptide preparation: The OSM **Tn** glycopeptides were prepared from asialo-OSM, which was dissolved in 15 mM phosphate buffered saline (PBS, pH 7.5), and digested with proteinase K (Sigma Chemical Co., St. Louis, MO; 10 mg glycoprotein/mg enzyme) at 37°C for 6 h, then at 65°C overnight. The precipitate was removed by centrifugation at 13000 rpm for 30 min. The supernatant was redigested by adding half the amount of proteinase K. Digestion was repeated three times. The glycopeptides were harvested and filtered through a molecular mass cut off (MMCO) 3000 membrane (Amicon Co., MA, USA). **Tn** glycopeptides used for this study were mixtures of **Tn** containing glycopeptides in the filtrable fraction (MMCO < 3000). The size distributions of **Tn** containing glycopeptides were examined by Bio-Gel P-2 (400 mesh) column chromatography using ddH₂O as eluant and dextran, raffinose (trisaccharide) and glucose as references.

Gal, *p*-NO₂-phenyl-αGalNAc, Galα1→3Galα1→methyl(**B**), Galα1→4Gal(**E**) and Galβ1→4Glc(**L**) were from Sigma Chemical Co., St. Louis, MO, USA.

2.4. Lectinochemical (binding) assays

Quantitative precipitin and precipitin-inhibition assays were performed using a microprecipitin technique [28] employing 5.0 μg of lectin nitrogen (N) mixed with varying amounts of glycoprotein. The mixture was incubated at 37°C for 1 h and kept at 4°C for 1 week. Total N in the washed precipitates was estimated by the ninhydrin method [29].

3. Results and discussion

In this paper, we expand the scope of this study and characterize the binding properties of GS I-A₄ with **Tn**(GalNAcα1→Ser/Thr) and galabiose ligand (Galα1→4Gal) by both quantitative precipitin (QPA) and precipitin-inhibition (QPIA) assays. During the past 2 decades, these analytical systems have been successfully used as valuable tools for characterizing saccharide-lectin interactions [14,15,19,30,31], as such studies can provide insight into the specificities and size parameters of lectin-glycan interactions. When the glycoforms, including human blood group **A**, **P**₁ and **Tn** active

Table 2
Inhibition of asialo porcine salivary glycoprotein-GS I-A₄ interactions by sugar inhibitors^a

Glycoprotein	Inhibition (%) ^b					
	0.28 μmol Galα1→3Galα1→methyl (B) added	0.35 μmol Galα1→4Gal (E) added	0.13 μmol Tn mixture added ^c	0.10 μmol <i>p</i> -NO ₂ -phenyl-α-GalNAc added	2.2 μmol Gal added	1.2 μmol Galβ1→4Glc (L) added
Asialo porcine salivary GP	81.8	78.5	99.4	100	86.7	1.8

^a5.0 μg N of lectin in a 3.0 ml glass centrifuge tube was mixed with or without (control) sugar inhibitor, 2.2 μmol Gal, 0.28 μmol Galα1→3Galα1→methyl, 0.35 μmol Galα1→4Gal, 1.2 μmol Galβ1→4Glc, 0.10 μmol *p*-NO₂-phenyl-α-GalNAc, 0.13 μmol **Tn** containing glycopeptide mixture, respectively, as inhibitors. After incubation at 37°C for 30 min, 7.5 μg of the corresponding glycoprotein was added, and subsequently incubated at the same temperature for 1 h and at 4°C for 6 days.

^b% of inhibition = (difference between A₅₇₀ of nitrogen content in the precipitate without and with inhibitor added/A₅₇₀ of nitrogen content in the precipitate without inhibitor added) × 100.

^cμmol GalNAc in **Tn** containing glycopeptides.

glycoproteins were tested by QPA, GS I-A₄ reacted strongly with both **Tn** containing glycoproteins purified from armadillo (Fig. 1a) and asialo ovine (Fig. 1b) submandibular glycoproteins, a P₁ active glycoprotein (Fig. 1c) isolated from sheep hydatid fluid [21,22], asialo porcine salivary glycoprotein (Fig. 1a), and a blood group A active glycoprotein MSM (Fig. 1d) isolated from human ovarian cyst fluid [26]. They precipitated over 80% of the lectin nitrogen added (Table 1) and 1.0–5.0 µg of each glycoprotein was required to achieve 50% precipitation. GS I-A₄ also bound well with the asialo bird nest glycoprotein (BN) from the salivary gland of the Chinese swiftlet which contains Galα1→4Gal residues at the non-reducing end of the carbohydrate chains [27] and precipitated about 72% of lectin nitrogen at the point of 30 µg asialo BN glycoprotein added (Fig. 1c and Table 1). GS I-A₄ did not precipitate fetuin (Fig. 1a), human α₁-acid glycoprotein, (Fig. 1d), native THGP Sd(a+) (Fig. 1b) and their asialo products that contain neither **Tn** nor **E** determinants [23,24,30]. Bovine and ovine submandibular glycoproteins were about one-half as reactive as their corresponding asialo products (Fig. 1b and 1d), because their **Tn** determinants are shielded by sialic acids. Native bird nest glycoprotein (Fig. 1c), in which most of the Galα1→4Gal sequences are masked by sialic acids [27], was inactive.

To establish that the asialo porcine salivary glycoprotein-GS I-A₄ interaction occurs through lectin determinants rather than being non-specific, three disaccharide determinants (Galα1→4Gal, Galα1→3Galα→methyl and Galβ1→4Glc), a mixture of **Tn** containing glycopeptides from asialo OSM (mainly of GalNAcα1→Ser/Thr peptides eluting near raffinose on BioGel P-2 column chromatography), *p*-NO₂-phenylαGalNAc and Gal were used to inhibit the lectin-asialo porcine salivary glycoprotein association. By inhibition of 5.0 µg N of lectin, 79–100% of the precipitation was inhibited by 0.28, 0.35, 0.13, 0.10 and 2.2 µmol of Galα1→3Galα→methyl, Galα1→4Gal, **Tn** glycopeptide mixtures, *p*-NO₂-phenylαGalNAc and Gal, respectively, but not at all or insignificantly with 1.2 µmol Galβ1→4Glc as a control (Table 2).

From the above results, it can be concluded that the **Tn** sequence (GalNAcα1→Ser/Thr) and the Galα1→4Gal disaccharide, in addition to blood group A (GalNAcα1→3Gal) and **B** (Galα1→3Gal), exhibit affinity for GS I-A₄.

Most plant tissues contain a single lectin, but many seeds contain two or more lectins that differ in their sugar specificities and other properties [32]. In the seeds of *G. simplicifolia*, several lectins are present for GalNAc, Gal or GlcNAc. At present, little knowledge is available concerning their physiological function. However, the results on the binding properties of GS I-A₄ suggest that this lectin might be useful as a reagent for detecting the presence of **A**, **Tn**, **B** and **E** determinants in glycoforms.

Acknowledgements: This work was supported by grants from the Chang-Gung Medical Research Project (CMRP No. 293), Kwei-san, Tao-yuan, Taiwan and the National Science Council (NSC 85-2331-B-182-079 and 84-2331-B-182-016), the National Health Institutes (DOH 85-HR-316 and DOH 84-HR-209), Department of Health, Taipei, Taiwan. This work was also supported by Grants 5RO1 A127508-03 and 2RO1 AI/GM19042-07 from the National Institutes of Health and DMB890-1840 from the National Science Foundation, USA.

References

- [1] Mäkelä, O. and Mäkelä, P. (1956) *Ann. Med. Exp. Biol. Fenn.* 31, 402–404.
- [2] Hayes, C.E. and Goldstein, I.J. (1974) *J. Biol. Chem.* 219, 1904–1914.
- [3] Murphy, L.A. and Goldstein, I.J. (1977) *J. Biol. Chem.* 252, 4739–4742.
- [4] Wood, C., Kabat, E.A., Murphy, L.A. and Goldstein, I.J. (1979) *Arch. Biochem. Biophys.* 198, 1–11.
- [5] Springer, G.F. (1984) *Science* 224, 1189–1206.
- [6] Hirohashi, S., Clausen, H., Yamada, T., Shimossato, Y. and Hakomori, S.I. (1985) *Proc. Natl. Acad. Sci. USA* 82, 7039–7043.
- [7] Kjeldsen, T., Clausen, H., Hirohashi, S., Ogawa, Y., Iijama, H. and Hakomori, S.I. (1988) *Cancer Res.* 48, 2214–2220.
- [8] Itzkowitz, S.H., Yuan, M., Montgomery, C.K., Kjeldsen, T., Takahashi, H.K., Bigbee, W.L. and Kim, Y.S. (1989) *Cancer Res.* 49, 197–204.
- [9] Itzkowitz, S.H., Bloom, E.J., Kokal, W.A., Modin, G., Hakomori, S.I. and Kim, Y.S. (1990) *Cancer* 66, 1960–1966.
- [10] Dahr, W., Uhlenbruck, G. and Bird, G.W.G. (1974) *Vox. Sang.* 27, 29–42.
- [11] Cartron, J.P., Andreu, G., Cartron, J., Bird, G.W.G., Salmon, C. and Gerbal, A. (1978) *Eur. J. Biochem.* 92, 111–119.
- [12] Cartron, J.P., Blanchard, D., Nurden, A., Cartron, J., Rahuel, C., Lee, D., Vainchenker, W., Testa, U. and Rochant, H. (1982) in: *Blood Groups and Other Cell Surface Markers in Health and Disease* (Salmon, C. ed.) pp. 34–54, Masson Publishing, New York.
- [13] Karlsson, K.A. (1989) *Annu. Rev. Biochem.* 58, 309–350.
- [14] Wu, A.M., Chin, L.K., Franz, H., Pfüller, U. and Herp, A. (1992) *Biochim. Biophys. Acta* 1117, 232–234.
- [15] Wu, A.M., Song, S.C., Wu, J.H. and Pfüller, U. (1995) *Biochim. Biophys. Acta* 1243, 124–128.
- [16] Tettamanti, G. and Pigman, W. (1968) *Arch. Biochem. Biophys.* 124, 41–50.
- [17] Wu, A.M. and Pigman, W. (1977) *Biochem. J.* 161, 37–47.
- [18] Wu, A.M., Wu, J.H. and Shen, F.S. (1994) *Biochem. Biophys. Res. Commun.* 198, 251–256.
- [19] Wu, A.M., Shen, F.S., Herp, A. and Wu, J.H. (1994) *Mol. Immunol.* 31, 485–490.
- [20] Wu, A.M., Shen, F.S., Herp, A., Song, S.C. and Wu, J.H. (1995) *FEBS Lett.* 360, 211–215.
- [21] Helene, T., Cory, A.D., Yates, A.S.R., Watkins, W.M. and Morgan, W.T.J. (1974) *Biochem. Biophys. Res. Commun.* 61, 1289–1296.
- [22] Morgan, W.T.J. and Watkins, W.M. (1964) *Proc. 9th Congr. Int. Soc. Blood Transfusion, Mexico*, 1962, pp. 225–229.
- [23] Donald, A.S.R., Yates, A.D., Soh, C.P.C., Morgan, W.T.J. and Watkins, W.M. (1983) *Biochem. Biophys. Res. Commun.* 115, 625–631.
- [24] Donald, A.S.R., Soh, C.P.C., Watkins, W.M. and Morgan, W.T.J. (1982) *Biochem. Biophys. Res. Commun.* 104, 58–65.
- [25] Kabat, E.A. (1956) *Blood Group Substances. Their Chemistry and Immunochemistry*, pp. 135–139, Academic Press, New York.
- [26] Wu, A.M. (1988) *Adv. Exp. Med. Biol.* 228, 351–394.
- [27] Wieruszki, J.M., Michalski, J.C., Montreuil, J., Strecker, G., Peter-Katalinic, J., Egge, H., Van Halbeek, H., Mutsaers, J.H.G.M. and Vliegthart, J.F.G. (1987) *J. Biol. Chem.* 262, 6650–6657.
- [28] Kabat, E.A. (1961) *Kabat and Mayer's Experimental Immunology*, 2nd edn., C.C. Thomas, Springfield, IL.
- [29] Schiffman, G., Kabat, E.A. and Thompson, W. (1964) *Biochemistry* 3, 113–120.
- [30] Wu, A.M., Lin, S.R., Chin, L.K., Chow, L.P. and Lin, J.Y. (1992) *J. Biol. Chem.* 267, 19130–19139.
- [31] Wu, A.M. and Sugii, S. (1988) *Adv. Exp. Med. Biol.* 228, 205–263.
- [32] Sharon, N. and Lis, H. (1989) *Lectins*, Chapman and Hall, New York.